MLIC
EVGN icon

Mandatum Life Insurance Company’s Evogene EVGN Stock Holding History

Mandatum Life Insurance Company’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$16K – 225
2015
Q4 		$16K Buy
+200
New +$14.9K ﹤0.01% 249

Other funds holding EVGN

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Mandatum Life Insurance Company's EVGN Position: Q1 2016 in Review

Mandatum Life Insurance Company sold out of Evogene (EVGN) in Q1 2016, closing a stake of 200 shares — an estimated $16K sold.

Mandatum Life Insurance Company first reported a position in EVGN in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 21 funds tracked by Wall St. Rank hold EVGN as of Q1 2016.

  • Mandatum Life Insurance Company reported no remaining Evogene position as of Q1 2016 after selling out during the quarter.
  • Mandatum Life Insurance Company sold 200 Evogene shares in Q1 2016, an estimated $16K.
  • Mandatum Life Insurance Company first reported a position in Evogene in Q4 2015 and held it in 1 quarter.
  • Mandatum Life Insurance Company's Evogene position peaked at $16K in Q4 2015.
  • 21 funds tracked by Wall St. Rank held Evogene as of Q1 2016.

Based on Mandatum Life Insurance Company's 13F filing for Q1 2016, filed 11 May 2016.